Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 15Multiple Myeloma 11Recurrence 8Ovarian Neoplasms 8Lymphoma 7Burkitt Lymphoma 7Pancreatic Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Hodgkin Disease 6Colorectal Neoplasms 6Myeloproliferative Disorders 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Biphenotypic, Acute 5Stomach Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia 4Hematologic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urogenital Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Osteosarcoma 3Melanoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, B-Cell 3

Interventions

thymoglobulin 1luspatercept 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
beta-Thalassemia × fludarabine × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡